soul trial oral semaglutide cardiovascular outcomes results 2024 nejm and in Patients with Type 2 Diabetes Oral Semaglutide Reduces Cardiovascular Events

The lawsuit also cites enforcement actions in multiple states and a separate 2025 lawsuit that accuses the company of selling counterfeit GLP-1 drugs

Determinations on the Safety Net status of providers will be made consistent with the process utilized in the completion of initial Safety Net status determinations and in the initial round of Safety Net Appeals

Similarly, neural therapy could offer additional benefits depending on individual circumstances

Future considerations of CTS include use of linked national registries to understand risk factors, explore possible screening methods, and evaluate diagnosis and treatment with a broader perspective beyond surgery, including psychological well-being